Why UCB Is Betting $1.15 Billion That Cell Therapy Can Change Epilepsy
The April 17, 2026 deal is a wager that a
Biotech’s IPO Window Is Reopening—But Only for Companies Wall Street Can Underwrite
The market is thawing, but not in the anything-goes way
The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing
On March 2, 2026, the U.S. Food and Drug Administration
Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T
On February 23, 2026, Gilead agreed to acquire Arcellx in
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
On February 9, Eli Lilly agreed to buy Orna Therapeutics
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
On a cold Tuesday in early January, Amgen quietly made
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here
A new generation of biotech start-ups is trying to “rejuvenate”
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
When a three-year-old from California flies to Manchester for a
A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong
Lonvi Biosciences says its procyanidin C1 capsule could, one day,
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
The explainable aging clock regulators might actually like
A new bioRxiv preprint introduces ACE—Aging Cell Embeddings—an explainable, deep-generative
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Madrid has put blood pressure back on the biotech map.
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Inside TCG Labs Soleil’s $400M Bet on Focused Biotech On
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)
European biotech received a confidence boost as the EU’s European
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech
A New Direction in Liquid Biopsy When Syantra Inc. announced
MOST POPULAR
